alpha-melanocyte-stimulating hormone suppresses bleomycin-induced collagen synthesis and reduces tissue fibrosis in a mouse model of scleroderma: melanocortin peptides as a novel treatment strategy for scleroderma?

Arthritis Rheum. 2009 Feb;60(2):592-603. doi: 10.1002/art.24228.

Abstract

Objective: Recently, we found that human dermal fibroblasts (HDFs) express melanocortin 1 receptors (MC-1R) that bind alpha-melanocyte-stimulating hormone (alpha-MSH). In search of novel therapies for scleroderma (systemic sclerosis [SSc]), we used the bleomycin (BLM) model to investigate the effects of alpha-MSH on collagen synthesis and fibrosis.

Methods: Collagen expression in HDFs was determined by real-time reverse transcription-polymerase chain reaction (RT-PCR) and Western blot analyses. Signal transduction studies included pharmacologic blockade, immunofluorescence analysis, Western blotting, and reporter-promoter assays. Oxidative stress was measured by fluorescence-activated cell sorter analysis, and anti-oxidative enzyme levels were determined by real-time RT-PCR and Western blot analyses. The effect of alpha-MSH in the BLM mouse model of scleroderma was assessed by histologic, immunohistochemical, real-time RT-PCR, and protein analyses. Expression of MC-1R and pro-opiomelanocortin (POMC) in skin and HDF samples from patients with SSc was determined by RT-PCR and compared with that in samples from normal controls.

Results: Treatment with alpha-MSH (and related peptides) suppressed BLM-induced expression of type I and type III collagen in HDFs, and this effect was cAMP-dependent. Neither BLM nor alpha-MSH altered Smad signaling, but antioxidants inhibited BLM-induced collagen expression in vitro. In addition, alpha-MSH suppressed BLM-induced oxidative stress and enhanced the expression of superoxide dismutase 2 (SOD2) and heme oxygenase 1 (HO-1). In the BLM mouse model, alpha-MSH reduced skin fibrosis and collagen content and increased tissue levels of SOD2 and HO-1. In skin and HDFs from patients with SSc, both MC-1R and POMC messenger RNAs were detected, but there were no differences compared with healthy controls.

Conclusion: Alpha-melanocyte-stimulating hormone and related peptides that exert their effects via MC-1R may provide a novel antifibrogenic therapeutic tool for the treatment of fibrotic diseases such as scleroderma.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Animals
  • Antibiotics, Antineoplastic / toxicity
  • Antioxidants / pharmacology
  • Bleomycin / toxicity
  • Collagen / biosynthesis
  • Collagen / drug effects*
  • Collagen / genetics
  • Dermis / drug effects
  • Dermis / metabolism
  • Dermis / pathology
  • Disease Models, Animal
  • Drug Antagonism
  • Fibroblasts / drug effects
  • Fibroblasts / metabolism
  • Fibrosis / chemically induced
  • Fibrosis / drug therapy*
  • Fibrosis / pathology
  • Gene Expression / drug effects
  • Heme Oxygenase-1 / genetics
  • Heme Oxygenase-1 / metabolism
  • Hormones / pharmacology*
  • Hormones / therapeutic use
  • Humans
  • Infant, Newborn
  • Male
  • Mice
  • Middle Aged
  • Oxidative Stress / drug effects
  • Pro-Opiomelanocortin / genetics
  • Pro-Opiomelanocortin / metabolism
  • RNA, Messenger / metabolism
  • Receptors, Melanocortin / drug effects*
  • Receptors, Melanocortin / genetics
  • Receptors, Melanocortin / metabolism
  • Scleroderma, Systemic / chemically induced
  • Scleroderma, Systemic / drug therapy*
  • Scleroderma, Systemic / pathology
  • Signal Transduction / drug effects
  • Superoxide Dismutase / genetics
  • Superoxide Dismutase / metabolism
  • Young Adult
  • alpha-MSH / pharmacology*
  • alpha-MSH / therapeutic use

Substances

  • Antibiotics, Antineoplastic
  • Antioxidants
  • Hormones
  • RNA, Messenger
  • Receptors, Melanocortin
  • Bleomycin
  • alpha-MSH
  • Pro-Opiomelanocortin
  • Collagen
  • Heme Oxygenase-1
  • Superoxide Dismutase